CVRx Creates Chief Commercial Officer Position
Posted on July 10, 2012 @ 10:13 am
Medical device company CVRx Inc. has created a new executive position to head its marketing department, chief commercial officer. The company attracted Philippe Wanstock, Ph.D., from Medtronic to take on this new role, where he will take responsibility for the global launch of CVRx’s Barostim neo product. Barostim neo has received CE Mark approval and is currently available in Germany, Italy, the Netherlands, Switzerland, and Austria.
Barostin neo is intended to treat hypertension and heart failure by helping trigger the body’s natural blood flow regulation systems that may not be functioning correctly. The system allegedly works by electrically activating the baroreceptors located in the carotid artery, the body's natural blood pressure sensors that regulate cardiovascular function. CVRx claims the system helps arteries to relax, making it easier for blood to flow through the body and reducing cardiac exertion; The heart to slow down, allowing more time for the organ to fill with blood; And kidneys to reduce fluid in the body, lowering both excessive blood pressure and workload on the heart.
Wanstok holds a master’s degree in economics from the Université Paris-Assas and a doctorate in finance and international marketing from the Université Panthéon Sorbonne, both in Paris, France.
"We are thrilled to have Philippe join the CVRx team," said Nadim Yared, president and CEO of CVRx. "Philippe's consistently superb track record of accomplishments in the active implantable medical device market makes him ideally suited to lead CVRx's worldwide commercial activities."
Wanstock expressed enthusiasm for CVRx’s technology: "The Barostim neo is an unparalleled technology for treating hypertension and heart failure," he said. "I am very excited to join CVRx to lead the commercial activities for this unique, game-changing therapy."
CVRx Inc. is a privately held company that is headquartered in Minneapolis, Minn.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.